AfricaRegulatory
African Pharmaceutical Regulatory Intelligence
TAMSULOSINE
8 registrations across 3 African markets— 5 active
Markets with TAMSULOSINE
Recent registrations
| Brand / Product | Market | Holder | Status | Expires |
|---|---|---|---|---|
| PROSTAM L.P Gélule à libération prolongée / 0.4 mg | 🇹🇳Tunisia | ADWYA | expired | Jan 2021 |
| MECIR LP Comprimé à libération prolongée / 0.4 MG | 🇹🇳Tunisia | BOEHRINGER INGELHEIM FRANCE | expired | Mar 2010 |
| PROSTAM L.P. Gélule à libération prolongée / 0.4 mg | 🇹🇳Tunisia | ADWYA | expired | Feb 2006 |
| UMAX 400 µG LP GELULE LP | 🇲🇦Morocco | — | active | — |
| UMAX 400 µG LP GELULE LP | 🇲🇦Morocco | — | active | — |
| UMAX 400 µG LP GELULE LP | 🇲🇦Morocco | — | active | — |
| PROSTAM gélule / 40% | 🇸🇳Senegal | ADWYA | active | — |
| UMAX 400 µG LP GELULE LP | 🇲🇦Morocco | — | active | — |
TAMSULOSINE in Africa — Regulatory Overview
TAMSULOSINE is registered across 3 African markets with 8 total product registrations on file. Data is sourced directly from official national drug regulatory authorities including Morocco, Tunisia, Senegal. AfricaRegulatory refreshes this data daily from official government sources.
Of the 8 registrations, 5 (63%) are currently active. Regulatory affairs teams use AfricaRegulatory to track registration expiry dates, identify market incumbents, and monitor approval status across African markets without manual monitoring of each national regulator.